Patent & Trade Mark
Attorneys
We are
Experts in Navigating IP in the Asia Pacific Region
Offices in
Thanks to many years of global experience, FB Rice has a network of trusted advisors in most key jurisdictions. We turn to those advisors when assisting our clients to promote their interests.

For specific information on our Asia Pacific capability, click here.
Joanne Martin

Partner

Joanne Martin
"Many Australian businesses look to China as offering opportunities for business growth both in China and globally. China is recognised as a complex and challenging market, however businesses trading successfully with China tend to be more competitive both domestically and in the international market in response to those learnings."
"Many Australian businesses look to China as offering opportunities for business growth both in China and globally. China is recognised as a complex and challenging market, however businesses trading successfully with China tend to be more competitive both domestically and in the international market in response to those learnings."
Australian High Court approves the Full Federal Court RPL Central decision and rejects appeal
Now that the RPL Central decision has been endorsed by the High Court, we expect IP Australia to refer to this decision more often during examination of computer implemented inventions. In particular, we expect IP Australia to raise patentable subject matter objections to claimed inventions where the substance of the invention is in the idea or business method, rather than in a new and useful effect in a computer.
Now that the RPL Central decision has been endorsed by the High Court, we expect IP Australia to refer to this decision more often during examination of computer implemented inventions. In particular, we expect IP Australia to raise patentable subject matter objections to claimed inventions where the substance of the invention is in the idea or business method, rather than in a new and useful effect in a computer.
03 March 2016
FB Rice Patent & Trade Mark Prosecution ranked Tier 1 by the MIP Stars survey
FB Rice is delighted to announce that for the first time ever, the firm is ranked Tier 1 in the annual Managing Intellectual Property for both Patent Prosecution and Trade Mark Prosecution.
FB Rice is delighted to announce that for the first time ever, the firm is ranked Tier 1 in the annual Managing Intellectual Property for both Patent Prosecution and Trade Mark Prosecution.
David Lee

Senior Associate

David Lee
David is a Senior Associate in the Engineering group of our Sydney office and holds a Bachelor of Science from Macquarie University, Sydney and a Masters in Industrial Property Law from the University of Technology, Sydney.
 
David is a registered Australian Patent and Trade Marks Attorney.
David is a Senior Associate in the Engineering group of our Sydney office and holds a Bachelor of Science from Macquarie University, Sydney and a Masters in Industrial Property Law from the University of Technology, Sydney.
 
David is a registered Australian Patent and Trade Marks Attorney.
20 April 2016
Proposed cuts to R&D tax Incentive Bill has lapsed.
The proposed 1.5% cut to the R&D tax incentive will not go ahead as the Bill before the Senate has lapsed, and will not proceed.
The proposed 1.5% cut to the R&D tax incentive will not go ahead as the Bill before the Senate has lapsed, and will not proceed.
Sale of a drug under confidentiality is not considered invalidating secret use under US post AIA
For US patent applications filed post introduction of the America Invents Act (AIA) (which changed from first-to-invent to first-to-file), sale and offer for sale made in confidence of a product that is subsequently patented will not count as prior disclosure in the United States. Put simply, secret use is not prior art for post-AIA applications.
For US patent applications filed post introduction of the America Invents Act (AIA) (which changed from first-to-invent to first-to-file), sale and offer for sale made in confidence of a product that is subsequently patented will not count as prior disclosure in the United States. Put simply, secret use is not prior art for post-AIA applications.